The urgent need for an effective biomarker for cytotoxic therapy-induced adverse effects

Simple item page
dc.contributor.authorGibson, R.
dc.date.issued2013
dc.description.statementofresponsibilityRachel J. Gibson
dc.identifier.citationCurrent Opinion in Supportive and Palliative Care, 2013; 7(2):153-154
dc.identifier.doi10.1097/SPC.0b013e32835e7f73
dc.identifier.issn1751-4258
dc.identifier.issn1751-4266
dc.identifier.orcidGibson, R. [0000-0002-4796-1621]
dc.identifier.urihttp://hdl.handle.net/2440/84481
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.rights© 2013 Wolters Kluwer Health. Lippincott Williams & Wilkins
dc.source.urihttps://doi.org/10.1097/spc.0b013e32835e7f73
dc.subjectIntestinal Mucosa
dc.subjectHumans
dc.subjectCitrulline
dc.subjectLeukocyte L1 Antigen Complex
dc.subjectAntineoplastic Agents
dc.subjectBreath Tests
dc.subjectRadiotherapy
dc.subjectHematopoietic Stem Cell Transplantation
dc.subjectToxicity Tests
dc.subjectBiomarkers
dc.titleThe urgent need for an effective biomarker for cytotoxic therapy-induced adverse effects
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Public Health publications